Navigating key news stories in pharma

Featured Stories

Featured
The Role of Artificial Intelligence in Antibody Drug Discovery
Future Biopharma
The Role of Artificial Intelligence in Antibody Drug Discovery
Future Biopharma

Traditional antibody discovery is notoriously slow and resource-intensive, but a new wave of AI tools is enabling optimization of candidates prior to them reaching the clinic, accelerating development timelines. 

Read More →
Future Biopharma
News
The Role of Artificial Intelligence in Antibody Drug Discovery
Future Biopharma
The Role of Artificial Intelligence in Antibody Drug Discovery
Future Biopharma

Traditional antibody discovery is notoriously slow and resource-intensive, but a new wave of AI tools is enabling optimization of candidates prior to them reaching the clinic, accelerating development timelines. 

Future Biopharma
The Need for Collaboration to Ensure Excipient Availability and Innovation
Strategy
The Need for Collaboration to Ensure Excipient Availability and Innovation
Strategy

In this deep-dive panel discussion moderated by The Pharma Navigator, several experts map out the future of excipients, addressing everything from climate-driven disruption to the need for greater industry collaboration.

Strategy
FDA Grants Priority Review of sBLA for Datopotamab Deruxtecan
Regulatory
FDA Grants Priority Review of sBLA for Datopotamab Deruxtecan
Regulatory

If the application is successful, the therapy will become the first-line treatment for patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.

Regulatory

R&D

Featured
Novo Nordisk Reveals Headline Phase III Trial Results Evaluating Combination Obesity Treatment
Novo Nordisk Reveals Headline Phase III Trial Results Evaluating Combination Obesity Treatment

The company’s fixed-dose combination treatment demonstrated superior efficacy to its individual components and was shown to be safe and well-tolerated, consisted with other incretin and amylin-based therapies.

Vetter Advances Next-Generation Tamper-Evident Syringe Closure Towards Launch
Vetter Advances Next-Generation Tamper-Evident Syringe Closure Towards Launch

The company has advanced its next‑generation tamper‑evident syringe closure from design finalization to industrialization ahead of a planned 2027 launch to strengthen its position in prefilled drug‑delivery solutions.

SGS Strengthens RSV Vaccine Research with Launch of Challenge Agent
SGS Strengthens RSV Vaccine Research with Launch of Challenge Agent

A new RSV A-strain challenge agent has been introduced by SGS to enhance CHIM studies and accelerate vaccine development. The breakthrough aims to generate more accurate, data-driven insights into RSV infection and immune response.

GSK, LTZ Therapeutics Collaborate on Next-Gen Immunotherapies
GSK, LTZ Therapeutics Collaborate on Next-Gen Immunotherapies

The companies will leverage GSK’s scientific expertise with LTZ’s immune engager platform to develop new first-in-class MCE therapies for the treatment of hematologic cancers and solid tumors.

Expansion

Featured
Novartis Invests in End-to-End Manufacturing in U.S.
Novartis Invests in End-to-End Manufacturing in U.S.

The company is creating a new flagship manufacturing hub in North Carolina that will enable end-to-end manufacturing of its key medicines in one geographic location.

Spinout Ensorcell Launches with Three Flagship Life Science Tools
Spinout Ensorcell Launches with Three Flagship Life Science Tools

Backed by the expert team and cutting-edge resources of Re:Build Manufacturing, Ensorcell will offer innovative, high-quality scientific tools designed to accelerate discoveries and improve patient outcomes.

Wilmington PharmaTech Secures Major Investment to Accelerate Expansion
Wilmington PharmaTech Secures Major Investment to Accelerate Expansion

A significant investment from Curewell Capital has been secured by Wilmington PharmaTech, providing growth capital to expand manufacturing and technology capabilities to accelerate drug development with U.S. manufacturing.

Lilly Grows European Manufacturing Capacity with New Facility in The Netherlands
Lilly Grows European Manufacturing Capacity with New Facility in The Netherlands

The USD 3 billion facility will expand the company’s capacity to produce oral medicines, enabling it to meet rising customer demand, and will also strengthen its global supply chain.

Dealmaking

Featured
Bio/Pharma M&A in the Year of Execution Certainty
Bio/Pharma M&A in the Year of Execution Certainty

With a looming patent cliff, continuing geopolitical pressures, and regionalized supply chains, there is a need for new creative deal structures and alternative financing to ensure successful M&A momentum.

Partnership Set Up to Address Growing Demand for Self-Administered Therapies
Partnership Set Up to Address Growing Demand for Self-Administered Therapies

A manufacturing collaboration between ten23 health and BD will support the commercialization of a wearable injector platform that offers a ready-to-use option for subcutaneous administration of high-dose biologics.

AbbVie, RemeGen Sign Exclusive Licensing Agreement for Novel Bispecific Antibody
AbbVie, RemeGen Sign Exclusive Licensing Agreement for Novel Bispecific Antibody

The agreement will allow AbbVie to develop, manufacture, and commercialize RemeGen’s novel PD-1/VEGF bispecific antibody in combination with its ADCs across multiple solid tumors.

Servier Taps Insilico's Pharma.AI in Multi-Billion Oncology Deal
Servier Taps Insilico's Pharma.AI in Multi-Billion Oncology Deal

Insilico Medicine has entered a multi‑year R&D collaboration with Servier to discover and develop novel AI‑designed oncology therapies. The deal will combine Insilico’s Pharma.AI platform with Servier’s global oncology development and commercialization capabilities.

Strategy

Featured
The Need for Collaboration to Ensure Excipient Availability and Innovation
The Need for Collaboration to Ensure Excipient Availability and Innovation

In this deep-dive panel discussion moderated by The Pharma Navigator, several experts map out the future of excipients, addressing everything from climate-driven disruption to the need for greater industry collaboration.

Delivering Success — The Importance of Considering Drug Delivery Early
Delivering Success — The Importance of Considering Drug Delivery Early

As chronic diseases rise globally, the bio/pharma industry is pivoting toward increasingly complex molecules that demand more sophisticated delivery strategies, which must be considered early on in development.

Cellular Origins Completes Series A Financing Round
Cellular Origins Completes Series A Financing Round

The raised funds, totaling USD 40 million, will be used to accelerate the company’s growth and to advance its robotic platform, Constellation, which enables flexible, scalable cell therapy manufacturing.

Lilly Cuts Price of Tirzepatide Single-dose Vials to Increase Patient Affordability
Lilly Cuts Price of Tirzepatide Single-dose Vials to Increase Patient Affordability

As demand for GLP-1 obesity drugs surges and affordability remains a competitive factor in the global weight-loss market, Eli Lilly slashes tirzepatide vial prices to boost access for self-pay patients.

Future Biopharma

Featured
The Role of Artificial Intelligence in Antibody Drug Discovery
The Role of Artificial Intelligence in Antibody Drug Discovery

Traditional antibody discovery is notoriously slow and resource-intensive, but a new wave of AI tools is enabling optimization of candidates prior to them reaching the clinic, accelerating development timelines. 

Weathering Headwinds: Bio/Pharma’s Roadmap for Success in 2026
Weathering Headwinds: Bio/Pharma’s Roadmap for Success in 2026

Despite geopolitical uncertainties, regulatory reforms, and fluctuating capital expenditure, the bio/pharma industry is entering 2026 with renewed focus and confidence.

The Outsourcing Pivot for Bio/Pharma Innovation
The Outsourcing Pivot for Bio/Pharma Innovation

Facing a world of political risk and scientific hurdles, pharma companies are downsizing internal footprints to focus on portfolio management while leaning on CDMOs for specialized execution, explains Owen Murray from Bend Bioscience.

Pharmapack 2026: Moving Toward a Large-Volume Future
Pharmapack 2026: Moving Toward a Large-Volume Future

From managing high viscosity to preventing agglomeration, the industry is shifting toward larger-volume, device-compatible solutions that prioritize both drug stability and healthcare efficiency, points out Dr. Robert Lindner from SCHOTT Pharma.

Regulatory

Featured
FDA Grants Priority Review of sBLA for Datopotamab Deruxtecan
FDA Grants Priority Review of sBLA for Datopotamab Deruxtecan

If the application is successful, the therapy will become the first-line treatment for patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.

Xenon Presents Clinical and Regulatory Milestones at J.P. Morgan Healthcare Conference
Xenon Presents Clinical and Regulatory Milestones at J.P. Morgan Healthcare Conference

The company is advancing its lead KV7 potassium channel modulator azetukalner through multiple Phase III trials in epilepsy and mood disorders, and planning its transition to commercial-stage growth.

MedPharm Strengthens Manufacturing Capabilities with Successful FDA Inspection
MedPharm Strengthens Manufacturing Capabilities with Successful FDA Inspection

The CDMO’s North Carolina facility has successfully completed an FDA inspection thereby validating its quality systems and commercial readiness to reinforce its position as a leader in complex topical and transdermal drug manufacturing.

AstraZeneca Gains Nod from FDA for Perioperative Imfinzi-Based Regimen
AstraZeneca Gains Nod from FDA for Perioperative Imfinzi-Based Regimen

The regulator’s decision will provide a new clinical option for patients with early gastric and gastroesophageal cancers that can deliver a significant survival benefit versus chemotherapy alone.

Upcoming Events

Featured
SCOPE 2026

Now in its 17th year, SCOPE returns February 2–5, 2026, to Rosen Shingle Creek in Orlando, Florida, bringing together the full clinical research ecosystem for four high-impact days of discussion, strategy, and networking.

IPEC Europe Excipients Forum 2026

Join IPEC in Torremolinos, Spain on Thursday 5 February 2026 to discover, experience and engage in stimulating discussions about the latest innovations and developments in the pharmaceutical excipients sector.

SLAS2026 International Conference & Exhibition

SLAS2026 delivers a fast-paced exhibition experience, including opportunities for business-to-business and business-to-consumer interactions.